Patent SG-11201807187X-A (SG)
Title: Binding members to pd-l1
Inventor: SHAMSHIEV ABDIJAPAR
IPC: C12N5/10
Filed: 2017-02-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property , Organization MINNIE 01E101011M HO 11111 0 1110101110M101111111 1111110 HOED International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/144681 Al 31 August 2017 (31.08.2017) WI PO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) C12N 5/10 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 35/17 (2015.01) A61K 39/395 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, PCT/EP2017/054367 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 24 February 2017 (24.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 16020057.2 25 February 2016 (25.02.2016) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: CELL MEDICA SWITZERLAND AG GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [CH/CH]; Wagistrasse 27, 8952 Schlieren (CH). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: SHAMSHIEV, Abdijapar; Buchzelgstrasse TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 64, 8053 Zurich (CH). KRETZSCHMAR, Titus; Son- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, nhaldenstrasse 63b, 6331 Hiinenberg (CH). DROSTE, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Miriam; Griinaustrasse 14, 8953 Dietikon (CH). PHIL- GW, KM, ML, MR, NE, SN, TD, TG). LIPS, Douglas; c/o Cell Medica Switzerland AG, Wagis- = trasse 27, 8952 Schlieren (CH). Declarations under Rule 4.17: Agent: STERLING IP; Orion House Bessemer Road, — as to the applicant's entitlement to claim the priority of the (74) = Welwyn Garden City AL7 1HH (GB). earlier application (Rule 4.17(iii)) [Continued on next page] Title: BINDING MEMBERS TO PD-L1 (54) = Figure 10 A — = = e 120 o — — = _ to 1 00 cc = _ O \" 80 . a o -8- scFv1 = — 0 60 a) -M- Positive Control _ = ° 40 C a) _ 1-1 .4 E 20 - - 73 cl) GC V::+ I— 0 g g g g iv 5 10 15 20 71- 1-1 Days after tumor cell injection IN 1-1 (57) : The present invention relates to anti- PD-L1 binding members and in particular to monovalent, high potency PD-L1- 0 binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of cancer and in - \" flammatory diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions. WO 2017/144681 Al 1#110HOMMEIROM 3010111111111110111111111111111111111111111111 • \"\"\"°\"\"`' — with sequence listing part of description (Rule 5.2(a)) — with international search report (Art. 21(3))